Clinical Trial Update: Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating allogeneic CD19-targeting CAR-γδT cells for relapsed/refractory Non-Hodgkin lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Allogeneic CD19-targeting CAR-γδT cell therapy

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Non Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: RECRUITING